Alzheimer's disease therapy - an update.

Area of Science:

• Neuroscience
• Pharmacology
• Gerontology

Background:

• Alzheimer's disease (AD) pathogenesis involves complex mechanisms including cholinergic deficits, inflammation, and oxidative stress.
• Current therapeutic strategies focus on symptomatic relief and disease modification.

Purpose of the Study:

• To review novel therapeutic approaches for Alzheimer's disease (AD) presented at the 5th International Geneva/Springfield Symposium.
• To highlight advancements in basic science data informing new AD treatments.

Main Methods:

• Review of pharmacological principles for cholinergic therapy, including acetylcholinesterase (AChE) inhibitors and receptor agonists.
• Exploration of anti-inflammatory agents (COX-2 inhibitors), hormone replacement therapy (estrogen), and antioxidants.
• Discussion of emerging drug candidates targeting the beta-amyloid cascade and other novel compounds.

Main Results:

• Several AChE inhibitors (tacrine, donepezil, rivastigmine, metrifonate) are in use.
• Numerous compounds targeting nicotinic/muscarinic receptors and inflammatory pathways are under investigation.
• Evidence suggests potential roles for estrogen, antioxidants (vitamin E, selegiline), and novel agents like iododoxorubicin in AD treatment.

Conclusions:

• Multiple therapeutic avenues are being explored for Alzheimer's disease, including cholinergic modulation, anti-inflammatory strategies, and antioxidant therapies.
• Emerging treatments aim to interfere with the beta-amyloid cascade and address other disease mechanisms.
• Future AD management may involve genotype analysis, early diagnosis, and environmental risk factor modification.